ClinicalTrials.gg
RecruitingNCT06182319Updated May 8, 2024

Optimizing Treatment of Adhesive Small Bowel Obstruction

A Phase 3 interventional study of Gastrografin and Saline in Adhesive Small Bowel Obstruction, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by University of California, Los Angeles · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Small bowel obstruction (SBO) is one of the most common causes of serious gastrointestinal disease in the US. Adhesion-related SBO (aSBO) is usually treated by the placement of a nasogastric tube (NGT) to decompress the stomach, administration of intravenous (IV) fluids and observation by a surgical team.

The purpose of this feasibility study is to determine the potential for implementation of treatment protocols for aSBO and determine the feasibility of randomizing patients with aSBO to receive or not receive NGTs or water-soluble contrast (WSC). The investigators will also determine the ability to measure HRQOL as a main outcome for the treatment of aSBO. The studies outlined in this research program intend to address gaps in knowledge about how to determine who benefits from NGT placement, who can be managed without them, how to objectively determine when a bowel obstruction has resolved, how to reintroduce feeding to patients with aSBO, what criteria should be used for hospital discharge and what role cathartics such as WSC contrast have in the management of aSBO.

This feasibility study will enroll a limited number of patients (n=40) who will be followed for up to 30 days.

02

Conditions studied

  • Adhesive Small Bowel Obstruction

Keywords

  • nasogastric tube (NGT)
  • water-soluble contrast (WSC)
  • Adhesion-related SBO (aSBO)
  • Small bowel obstruction (SBO)
03

In context

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 194 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age.
  2. Documentation of aSBO as evidenced by one or more clinical features meeting the following criteria: Nausea, emesis, abdominal pain, distended abdomen CT evidence of aSBO

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, breastfeeding, or unwilling to practice during participation in the study.
  2. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
  3. Unstable angina or recent myocardial infarction (MI)/stroke within 6 months
  4. Nonadhesive SBO

    1. Paralytic Ileus
    2. Incarcerated hernia
    3. Fecal impaction
    4. Intra-abdominal Early aSBO within 4 weeks of a prior abdominal operation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SBO treated without NG tube

    Patients who decline NG intubation will be enrolled in the trial, followed prospectively and have the same outcome measures as are acquired in the other study arms.

    Procedure: SBO Treatment Without NG Tubes

  • Experimental
    SBO treated with NG tube and Water-Soluble Contrast (WSC)

    Patients who select NG tube treatment will be randomized into experimental and control groups. The experimental groups will have 100 cc of WSC administered in the NG tube within 2 hours of NG tube placement.

    Drug: Gastrografin

  • Placebo comparator
    SBO Treated with NG tube and Placebo

    The control group will have 100cc of saline administered via the NG tube within 2 hours of NG tube placement.

    Drug: Saline

Interventions

  • DrugDiatrizoate MeglumineStudies of Diatrizoate MeglumineDiatrizoate Meglumine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of WSC (Gastrografin) 2 hours after placement of NGT.

  • DrugSaline

    Administration of Saline 2 hours after placement of NGT.

  • ProcedureSBO Treatment Without NG Tubes

    Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial

06

What researchers measure

Primary outcomes

  1. Patient-Reported Outcomes Measurement Information System (PROMIS®)-29

    Quality of life will be assessed using the PROMIS-29 HRQOL instrument. The survey uses multiple response formats. A total score provides an index of HRQOL, with higher scores on a scale of 0-100 reflecting better HRQOL.

    Time frame: The measure will be obtained at baseline when a diagnosis of aSBO is made, at hospital day 1, the day after an NGT is removed, the day a patient is discharged from the hospital and at 30 days after discharge.

07

Study locations

1 of 1 sites recruiting
  • University of California, Los Angeles, David Geffen School of Medicine
    Los Angeles, California 90024, United States
    Recruiting
    • · Contact310-825-2631
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 26, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 15, 2025
CompletionEst.
Dec 15, 2025
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06182319
Responsible party
Edward Harry Livingston (Professor of Surgery, University of California, Los Angeles) — Principal investigator
First posted
Dec 26, 2023
Start date
Jan 1, 2024
Primary completion
Dec 15, 2025 (estimated)
Completion
Dec 15, 2025 (estimated)
Last update
May 8, 2024

Study contacts

Steven Stokes
Contact
sstokes@mednet.ucla.edu
310-206-7436
Edward H Livingston, MD
Contact
310-794-7788

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diatrizoate Meglumine

Start the discussion